A new study from the University of Nebraska Medical Center suggests a correlation between cholesterol-lowering drugs taken during pregnancy and a higher risk of autism in children.
Study Findings and Methodology
Researchers analyzed over 6.14 million medical records from the Epic Cosmos database, covering nearly one-third of all births in the U.S. between 2014 and 2023. The analysis revealed a consistent link between prenatal exposure to drugs that inhibit cholesterol synthesis and an increased incidence of autism spectrum disorder (ASD) in offspring.
Mothers prescribed at least one cholesterol synthesis-inhibiting medication (SBIM) during pregnancy had a 1.47 times higher risk of their child being diagnosed with ASD. This risk increased with dosage, with a 2.33-fold increase observed in cases where four or more SBIMs were prescribed concurrently.
Drugs Investigated and Grouping
The research team categorized medications based on their common effects on sterol biosynthesis, rather than by indication. This approach differed from previous studies.
The 14 generic drugs examined included aripiprazole, atorvastatin, bupropion, buspirone, fluoxetine, haloperidol, metoprolol, nebiwolol, pravastatin, propranolol, rosuvastatin, sertraline, simvastatin, and trazodone. Collectively, these medications account for over 400 million prescriptions annually in the U.S.
Cholesterol’s Role in Fetal Development
Cholesterol is crucial for fetal development, particularly brain development, which is the organ richest in cholesterol. The fetal brain begins producing its own sterols around 19-20 weeks of gestation. Genetic disruptions in this metabolic pathway can lead to severe developmental disorders, such as Smith-Lemli-Opitz syndrome (SLOS), where up to 75% of children meet criteria for ASD.
Growing Use of SBIMs During Pregnancy
The use of SBIMs during pregnancy has increased significantly over time, rising from 4.3% of pregnancies in 2014 to 16.8% in 2023.
Expert Commentary and Cautions
Dr. Karoly Mirnics, director of the UNMC’s Unroe-Meyer Institute, emphasized that the findings do not suggest these medications are unsafe for adults. However, she highlighted the importance of addressing potential risks associated with their use during pregnancy, when even minor biochemical disturbances can significantly impact fetal brain development.
Researchers stress that pregnant patients should not discontinue or alter medication regimens without medical supervision, as many SBIMs are essential for treatment and can be life-saving. The study underscores the need for reassessing prescribing practices and developing safer alternatives for use during pregnancy.
Recommendations for Future Research and Practice
The research team recommends creating a comprehensive list of sterol-inhibiting drugs, screening new drugs for unintended sterol pathway inhibition, and educating physicians about sterol-related disorders linked to medication use during pregnancy. They also suggest identifying genetically predisposed patients and exploring safer alternatives when possible.